47 results on '"O'Neil B"'
Search Results
2. 127P A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
3. 660MO First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase I study (SGNB7H4V-001)
4. 20 Outcome Study of Mild Traumatic Brain Injury Patients Integrating a Brain Electrical Activity-Based Decision Rule
5. EP08.02-116 Design of a Phase 1 Study of AMG 193, an MTA-Cooperative PRMT5 Inhibitor, in Patients with Advanced MTAP-Null Solid Tumors
6. 1198TiP A phase Ib/II open-label, nonrandomized study of FGFR inhibitor futibatinib in combination with MEK inhibitor binimetinib in patients with advanced KRAS-mutant cancer
7. Coccidioidomycosis in non-endemic areas: a case series
8. 432P Pembrolizumab (pembro) for previously treated, microsatellite instability–high (MSI-H)/mismatch repair–deficient (dMMR) metastatic colorectal cancer (mCRC): Final analysis of KEYNOTE-164
9. 113P - A Phase I Study of an Anti-IDO1 Inhibitor (LY3381916) as Monotherapy and in Combination with an Anti-PD-L1 Antibody (LY3300054) in Patients with Advanced Cancer
10. 717P - Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic ductal adenocarcinoma patients treated with FOLFIRINOX
11. 299 Retrospective Study of a Low-Risk Chest Pain Protocol in a Socioeconomically Disadvantaged Population
12. PCN41 - Supporting Individual Reflection and Patient-Clinician Shared Decision-Making on GEP-NET Management Options Using Reflective Multi-Criteria Decision Analysis
13. LBA-002 - A phase 1b/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabptx) in metastatic pancreatic adenocarcinoma (mpdac) patients (pts)
14. P-385 - CanStem111P trial: A phase III study of napabucasin plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC)
15. EP-1277: Optimising RT dose for anal cancer - the development of three clinical trials in one platform
16. PRM166 - What Matters Most? An Exploration of Decision Criteria Considered by Patients with GEP-NET and Physicians Using Holistic Multi-Criteria Decision Analysis
17. PRM156 - To Treat or Watch? Identifying Drivers of Decisions for Patients with GEP-NET Using Reflective Multi-Criteria Decision Analysis
18. 677P - Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC)
19. 464PD - A multi-center, randomized, double-blind phase II trial of FOLFIRI + regorafenib or placebo for patients with metastatic colorectal cancer who failed one prior line of oxaliplatin-containing therapy
20. 367PD - Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC)
21. 314 Timing and Rationale of Withdrawal of Life-Sustaining Treatment After the Implementation of Target Temperature Management Post Cardiac Arrest
22. 105 Ultrasound-Enhanced Catheter-Directed Thrombolysis for Patients With Massive and Submassive Pulmonary Embolism Presenting to the Emergency Department
23. PRM99 - CAN HOLISTIC MCDA TACKLE ISSUES RAISED BY EVALUATING TREATMENTS FOR RARE DISEASES: AN EXPLORATION FROM THE HTA PERSPECTIVE
24. PMS87 - RECENT EVOLUTION OF THE MARKET FOR BIOLOGIC AND NON-BIOLOGIC DRUGS MODIFYING RHEUMATOID ARTHRITIS AMONG ADULT PATIENTS IN CANADA
25. PND58 - Impact Of New Entrants To The Market For Multiple-Sclerosis Disease-Modifying Drugs In Canada
26. 2039 Phase IB/II study of neoadjuvant chemoradiotherapy with CRLX101 and capecitabine for locally advanced rectal cancer
27. PDB94 - Evolution of the Market for oral Antidiabetic agents In Canada after Introduction of Dipeptidyl Peptidase-4 Inhibitors
28. 305 Efficiency and Effectiveness of a Chest Pain Protocol in an Urban Hospital Emergency Department
29. LBA10 - Calgb/Swog 80405: Analysis of Patients Undergoing Surgery As Part of Treatment Strategy
30. O-0019 - CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (MFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (PTS) with KRAS Wild-Type (WT) Untreated Metastatic Adenocarcinoma of the Colon
31. (269) Circulating microRNA evaluated in the early aftermath of motor vehicle collision predict widespread pain development in African Americans and provide potential pathogenic insights: results of a preliminary analysis
32. Comparison of End Tidal CO2 and Cerebral Oximetry in Determining Return of Spontaneous Circulation During Cardiopulmonary Resuscitation
33. 260 The Predictive Value of a Hand-held EEG Acquisition Device in Patients With Closed Head Injury
34. 212 End Tidal CO2 versus Cerebral Oximetry for Monitoring CPR Quality and Determination of Return of Spontaneous Circulation
35. 211 Comparison of Emergency Department and Out-of-Hospital Cardiac Arrest Patients Monitored With End Tidal CO2 and Cerebral Oximetry
36. 158 Utility Cranial Nerve Testing Obtained in the Emergency Department as Early Predictors of Neurologic Outcome Post Cardiac Arrest
37. 162 Can Quantitative Brain Electrical Activity Aid in the Triage of Mild Traumatic Brain Injured Patients?
38. 160 Utility of Hand-held EEG Device in Predicting Post-concussion Syndrome in Patients With Closed Head Injury
39. 26 Using Cerebral Oxiemtry To Predict Return of Spontaneous Circulation
40. 281 POSTER Phase I and pharmacokinetic study of MLN8054, a selective inhibitor of Aurora A kinase
41. 280 POSTER Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United States
42. 12: Physician Assistant Productivity and Profit in an Emergency Department Fast-Track Area
43. 35: Hypothermia Versus Normothermia After Out-of-Hospital Cardiac Arrest: Survival to Discharge and Neurologic Outcomes
44. 14: Performance of an ED-Based PICC Line Service
45. The emergency department transient ischemic attack accelerated diagnostic protocol (TIA ADP) study
46. PRIME ECG improves emergency department diagnosis and management in moderate- to high-risk unstable angina/non–ST elevation myocardial infarction patients
47. Clinical and pathological findings in feline immunodeficiency virus experimental infection
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.